Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Takeda Pharmaceutical Co Ltd And Zinfandel Pharmaceuticals Ltd Initiate Phase 3 TOMMORROW Trial Of AD-4833 For The Delay Of Onset Of Mild Cognitive Impairment Due To Alzheimer's Disease

Monday, 26 Aug 2013 11:40am EDT 

Takeda Pharmaceutical Co Ltd And its partner, Zinfandel Pharmaceuticals Ltd announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm. 

Company Quote

15.0 +0.25%
27 Feb 2015